ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,559Medicare Part D Prescriptions Filled, Including Refills

Rank: 29 out of 315

$689K Total Retail Price of All Prescriptions

Rank: 34 out of 315

657 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
14% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Hawaii
Lower avg

Schedule Two
Controlled Substances

2% of this provider’s 657 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

7% of this provider’s 657 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

1% of this provider’s 9,617 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$65 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Hawaii
LOSARTAN POTASSIUM 708 678 1 4
LOVASTATIN 449 417 2 8
PRAVASTATIN SODIUM 379 333 3 10
AMLODIPINE BESYLATE 373 331 4 2
LEVOTHYROXINE SODIUM 318 291 5 6
OMEPRAZOLE 305 277 6 9
FELODIPINE ER 291 282 7 23
ATENOLOL 255 246 8 11
ATORVASTATIN CALCIUM 224 215 9 5
VITAMIN D2 216 212 10 134
TAMSULOSIN HCL 202 185 11 21
LOSARTAN-HYDROCHLOROTHIAZIDE 201 183 12 17
METFORMIN HCL 183 152 13 7
FUROSEMIDE 183 180 13 15
HYDROCODONE-ACETAMINOPHEN 177 143 S3 15 19
ZOLPIDEM TARTRATE 172 163 16 29
METOPROLOL SUCCINATE 172 149 16 13
POLYETHYLENE GLYCOL 3350 162 153 18 106
HYDROCHLOROTHIAZIDE 151 144 19 16
WARFARIN SODIUM 138 137 20 20
ALLOPURINOL 137 130 21 14
ALENDRONATE SODIUM 135 125 22 12
FAMOTIDINE 130 126 23 75
DOXAZOSIN MESYLATE 120 112 24 110
GLIMEPIRIDE 115 104 25 32
JANUVIA 113 113 26 31
LISINOPRIL 112 93 27 3
MUPIROCIN 98 81 28 110
METFORMIN HCL ER 96 83 29 33
ADVAIR DISKUS 91 82 30 46
POTASSIUM CHLORIDE 89 89 31 36
PANTOPRAZOLE SODIUM 85 84 32 35
GABAPENTIN 79 63 33 37
FINASTERIDE 74 74 34 60
TRIAMTERENE-HCTZ 70 70 35 71
DEXAMETHASONE 68 61 36 241
LIPITOR 66 59 37 44
COMBIVENT 65 44 38 169
ZETIA 65 64 38 84
BENZONATATE 64 64 40 216
NAMENDA 62 62 41 38
CARVEDILOL 61 61 42 22
DONEPEZIL HCL 60 60 43 28
GLYBURIDE 54 54 R 44 49
AZITHROMYCIN 53 50 45 39
SYNTHROID 50 50 46 51
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 16, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.